Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) held a Type A meeting with the FDA on June 27, 2022, to discuss the NDA resubmission for VP-102, aimed at treating molluscum contagiosum. The company expressed satisfaction with the FDA's collaborative approach regarding stability data and post-approval options. VP-102 could become the first FDA-approved treatment for this contagious skin disease affecting six million people, primarily children. In addition, VP-102 has completed Phase 2 studies for common and external genital warts, highlighting Verrica's commitment to dermatological needs.
Verrica Pharmaceuticals announced that the FDA issued a Complete Response Letter (CRL) for its NDA for VP-102, intended for treating molluscum contagiosum. The CRL cites deficiencies related to Sterling Pharmaceuticals' OAI status, although no issues with VP-102 manufacturing were reported. While FDA's review of the NDA was completed, the agency cannot communicate the label until Sterling's status is resolved. Verrica is exploring options to address the OAI classification and may engage an alternative supplier. The firm is committed to FDA collaboration and plans to request a Type A meeting shortly.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced its Q1 2022 financial results, highlighting significant developments as it prepares for the potential FDA approval of VP-102, with a PDUFA goal date of May 24, 2022, for treating molluscum. The company reported license revenues of $0.4 million, a decrease from $12 million in Q1 2021, alongside a GAAP net loss of $8.5 million or $0.31 per share. Research and development expenses fell to $2.7 million, while cash reserves totaled $61.9 million, projected to sustain operations into Q3 2022.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced participation of CEO Ted White in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 p.m. ET. Investors can access a live webcast of the event through the provided link or on Verrica's website, with a replay available for 30 days post-event. The company focuses on developing treatments for dermatological conditions, including its leading candidate VP-102 for molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica holds a licensing agreement with Lytix Biopharma for LTX-315.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the dosing of the first patient in its Phase 2 trial of LTX-315, an innovative oncolytic peptide targeting basal cell carcinoma (BCC). With 3-4 million BCC diagnoses annually in the U.S., the trial aims to provide a non-surgical treatment option, addressing a significant unmet medical need. The study will evaluate safety and efficacy in approximately 66 adult subjects. LTX-315 has shown promising immune responses in earlier trials and could potentially expand to treat squamous cell carcinoma in the future.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported a net loss of $9.5 million for Q4 2021, down from $13.0 million in Q4 2020. Full-year net loss was $35.1 million or $1.30 per share, compared to $42.7 million or $1.71 per share in 2020. The company recognized $12 million in license revenues for 2021. Research and development expenses rose to $3.4 million in Q4 2021, mainly due to increased manufacturing costs. Upcoming milestones include a PDUFA date of May 24, 2022, for VP-102 and a Phase 2 trial for LTX-315 in basal cell carcinoma set to begin in early 2022.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that President and CEO Ted White will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on March 9, 2022, at 11:10 a.m. ET. The event will be accessible via a live webcast, and a replay will be available for 30 days post-event. Verrica focuses on developing dermatology therapeutics, including its late-stage product candidate, VP-102, aimed at treating molluscum and common warts, and VP-103 for plantar warts. The company has also licensed LTX-315 for dermatologic oncology.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the FDA accepted its resubmitted New Drug Application (NDA) for VP-102, targeting the treatment of molluscum contagiosum. The FDA granted a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022. VP-102 aims to be the first FDA-approved treatment for this highly contagious skin disease affecting approximately six million people in the U.S., particularly children. The resubmission includes limited changes, and the company is optimistic about the demand for an effective treatment.
Verrica Pharmaceuticals (Nasdaq: VRCA) has resubmitted the New Drug Application (NDA) for VP-102, aimed at treating molluscum contagiosum, to the FDA. This resubmission addresses deficiencies noted in the Complete Response Letter from September 2021, including inspection issues and user interface recommendations. CEO Ted White anticipates a 2-month review period, with a potential launch of VP-102 as the first FDA-approved treatment for this viral skin disease affecting six million people, primarily children, in the U.S. annually.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the FDA's acceptance of its IND application for LTX-315, a novel oncolytic peptide for treating basal cell carcinoma, a prevalent form of skin cancer. The Phase 2 trial is expected to begin in Q1 2022. With over 5 million non-melanoma skin cancer diagnoses annually in the U.S., LTX-315 aims to offer a non-surgical treatment option. The drug shows promise in inducing immune responses against tumors and aims to improve patient outcomes compared to current surgical options.